BlackRock
ACRS icon

BlackRock’s Aclaris Therapeutics ACRS Stock Holding History

BlackRock’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.8M Buy
7,407,065
+602,224
+9% +$2.03M ﹤0.01% 2874
2025
Q4 		$20.5M Buy
6,804,841
+1,113,489
+20% +$2.81M ﹤0.01% 3096
2025
Q3 		$10.8M Buy
5,691,352
+176,473
+3% +$308K ﹤0.01% 3414
2025
Q2 		$7.83M Buy
5,514,879
+4,153,842
+305% +$5.62M ﹤0.01% 3548
2025
Q1 		$2.08M Buy
1,361,037
+103,258
+8% +$220K ﹤0.01% 3986
2024
Q4 		$3.12M Sell
1,257,779
-454,018
-27% -$1.13M ﹤0.01% 3904
2024
Q3 		$1.97M Sell
1,711,797
-320,358
-16% -$393K ﹤0.01% 4004
2024
Q2 		$2.24M Sell
2,032,155
-3,169,992
-61% -$3.73M ﹤0.01% 3936
2024
Q1 		$6.45M Sell
5,202,147
-703,725
-12% -$839K ﹤0.01% 3565
2023
Q4 		$6.2M Buy
5,905,872
+297,982
+5% +$909K ﹤0.01% 3603
2023
Q3 		$38.4M Buy
5,607,890
+13,717
+0.2% +$117K ﹤0.01% 2558
2023
Q2 		$58M Buy
5,594,173
+478,800
+9% +$4.33M ﹤0.01% 2394
2023
Q1 		$41.4M Buy
5,115,373
+26,714
+0.5% +$339K ﹤0.01% 2576
2022
Q4 		$80.1M Buy
5,088,659
+278,361
+6% +$4.48M ﹤0.01% 2156
2022
Q3 		$75.7M Buy
4,810,298
+140,382
+3% +$2.21M ﹤0.01% 2142
2022
Q2 		$65.2M Buy
4,669,916
+682,809
+17% +$9.57M ﹤0.01% 2308
2022
Q1 		$68.7M Sell
3,987,107
-91,768
-2% -$1.25M ﹤0.01% 2378
2021
Q4 		$59.3M Buy
4,078,875
+290,458
+8% +$4.4M ﹤0.01% 2535
2021
Q3 		$68.2M Buy
3,788,417
+549,368
+17% +$8.81M ﹤0.01% 2454
2021
Q2 		$56.9M Buy
3,239,049
+2,254,173
+229% +$51.2M ﹤0.01% 2609
2021
Q1 		$24.8M Buy
984,876
+11,706
+1% +$229K ﹤0.01% 3065
2020
Q4 		$6.3M Sell
973,170
-67,200
-6% -$283K ﹤0.01% 3603
2020
Q3 		$2.67M Sell
1,040,370
-7,446
-0.7% -$16.7K ﹤0.01% 3818
2020
Q2 		$1.7M Sell
1,047,816
-1,578,705
-60% -$2.12M ﹤0.01% 3871
2020
Q1 		$2.73M Sell
2,626,521
-13,048
-0.5% -$17.8K ﹤0.01% 3565
2019
Q4 		$4.99M Sell
2,639,569
-392,200
-13% -$650K ﹤0.01% 3499
2019
Q3 		$3.27M Buy
3,031,769
+48,660
+2% +$69K ﹤0.01% 3605
2019
Q2 		$6.53M Sell
2,983,109
-149,824
-5% -$817K ﹤0.01% 3440
2019
Q1 		$18.8M Sell
3,132,933
-487,902
-13% -$3.23M ﹤0.01% 2774
2018
Q4 		$26.8M Buy
3,620,835
+1,103,423
+44% +$11.4M ﹤0.01% 2569
2018
Q3 		$36.6M Buy
2,517,412
+205,771
+9% +$3.53M ﹤0.01% 2550
2018
Q2 		$46.2M Buy
2,311,641
+204,215
+10% +$3.77M ﹤0.01% 2402
2018
Q1 		$36.9M Sell
2,107,426
-87,602
-4% -$1.86M ﹤0.01% 2440
2017
Q4 		$54.1M Buy
2,195,028
+485,146
+28% +$11.8M ﹤0.01% 2242
2017
Q3 		$44.1M Buy
1,709,882
+510,356
+43% +$13.7M ﹤0.01% 2361
2017
Q2 		$32.5M Buy
1,199,526
+418,483
+54% +$11.4M ﹤0.01% 2502
2017
Q1 		$23.3M Buy
781,043
+780,343
+111,478% +$22.5M ﹤0.01% 2661
2016
Q4 		$19K Buy
700
+200
+40% +$5.1K ﹤0.01% 3262
2016
Q3 		$13K Sell
500
-349
-41% -$7.4K ﹤0.01% 3354
2016
Q2 		$16K Buy
849
+500
+143% +$9.91K ﹤0.01% 3319
2016
Q1 		$7K Buy
+349
New +$6.67K ﹤0.01% 3261

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BlackRock's ACRS Position: Q1 2026 in Review

BlackRock increased its Aclaris Therapeutics (ACRS) stake by 8.8% in Q1 2026, buying an estimated $2.03M and bringing the position to 7,407,065 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

BlackRock first reported a position in ACRS in Q1 2016 and has held it in 41 quarters since. The position peaked at $80.1M in Q4 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • BlackRock held 7,407,065 shares of Aclaris Therapeutics worth $27.8M as of Q1 2026.
  • BlackRock bought 602,224 Aclaris Therapeutics shares in Q1 2026, an estimated $2.03M.
  • Aclaris Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2874 holding.
  • BlackRock first reported a position in Aclaris Therapeutics in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's Aclaris Therapeutics position peaked at $80.1M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.